STEP Trial: Allogeneic stem cell therapy for the treatment of knee osteoarthritis

The company completed a Phase I safety trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability. The study shows that a single injection into the knee of either dose of Progenza in patients appeared safe and well tolerated. Progenza also showed durable and clinically meaningful pain relief.

ACTIVATE Trial: Autologous cancer vaccine for patients with advanced cancers

The company completed a Phase I safety trial of its cancer vaccine which met the primary endpoint of safety and tolerability.

RGSH4K also showed encouraging signs of immune stimulation in some patients, as demonstrated by changes in cancer markers, immune cells and cytokines. This immune stimulation was seen in one or more patients at all three dose levels. Preliminary indications of anti-tumour activity were seen in some patients however long term follow up on 50% of the patients continues.

Cell identification and selection technology for chronic pain

Regeneus, in collaboration with Macquarie University and University of Adelaide have been awarded a $340,000 Linkage Grant by the Australian Research Council for a 3 year research project which will seek to develop a better understanding of chronic pain and how it affects women and men differently and how stem cells specially selected for their cytokine profiles can be used to relieve chronic pain in animals and help lay the foundations for future human therapies.